GlassScriptPhysician profile
Jenny Machuca
NPI 1578550943
$15,383.54
in general payments reported to CMS, 2019-2025
37 companies · $2,368 in 2025
The $2,368 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,409 · 2020: $1,199 · 2021: $1,778 · 2022: $2,188 · 2023: $2,645 · 2024: $2,797 · 2025: $2,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,775 · Education: $34.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,775.00 |
| Education | $34.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,147.95 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,544.66 | 2019-2025 | Ofev, Spiriva, Spiriva Respimat |
| Glaxosmithkline, LLC. | $2,371.82 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genentech USA, INC. | $883.08 | 2019-2022 | |
| Amgen INC. | $807.03 | 2022-2025 | Tezspire |
| Genzyme Corporation | $507.06 | 2021-2025 | |
| Insmed, INC. | $482.20 | 2019-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $400.04 | 2019-2024 | Yupelri |
| Baxter Healthcare | $349.59 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Volara System |
| Regeneron Healthcare Solutions, INC. | $295.01 | 2019-2025 | Dupixent |
| Verona Pharma, INC. | $275.89 | 2025 | Ohtuvayre |
| Dilon Technologies, INC. | $226.94 | 2023-2024 | Hemoblast Bellows |
| Fisher & Paykel Healthcare INC | $196.56 | 2024-2025 | Fisher & Paykel Healthcare |
| Advanced Respiratory, INC | $194.69 | 2019-2021 | |
| Optinose US, INC. | $189.66 | 2019-2020 |
Show all 36 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Machuca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.